Biomarker Core

项目总结--生物标志物核心 探索性的范德比尔特阿尔茨海默病研究中心(VADRC)Biomarker Core将利用 Vanderbilt在蛋白质组学、神经成像和遗传学方面的机构优势，提供可扩展的 可支持生物标志物收集、存储、分析、集成和分发的基础设施。在.之下 在蒂莫西·霍曼博士的领导下，我们已将范德比尔特公司确立为临床前基因组学核心 阿尔茨海默病协会，为阿尔茨海默病患者的多部位队列和尸检研究建立了Biomarker Core 阿尔茨海默病与痴呆性妄想的相关性，导致多项大规模发现和候选 蛋白质组分析强调阿尔茨海默病风险和韧性的新标记物，并建立了 来自阿尔茨海默病数据库的弹性，一个协调体液的本地生物标记物数据库， 10项独立队列研究中的神经成像和基因组数据。对于P20，我们将利用我们的 当地丰富的基础设施和资源，可获得强大的体液、神经成像和遗传生物标记物 VADRC内的临床核心和附属队列研究。生物标记物核心和临床核心将发挥作用 密切确保使用既定的标准化方案适当收集相关生物标志物，以反映 当前最佳实践。流体、神经成像和遗传数据将被处理并存储在 建立关系数据库，Biomarker核心将工作以确保适当的存储和处理 所有样品和数据，并有多种质量控制措施到位。临床核心中心收集的样本 将由Biomarker Core整合到资助的、正在进行的项目中，以支持VADRC的主题 重点建立对非淀粉样蛋白损伤途径的有效预防和治疗策略 通常与阿尔茨海默病的核心病理同时发生。例子包括发现蛋白质组项目 使用质谱学，通过临床前阿尔茨海默病联盟进行的神经成像项目，以及 基因组学项目是阿尔茨海默病遗传学联合会和阿尔茨海默病协会的一部分 测序项目。所有数据将与大规模队列研究协调一致，Biomarker Core将 与行政核心协调，分发所有生物标志物数据，以支持地方和国家研究 活动。Biomarker Core还将促进生物显微镜收集、神经成像方面的教育活动 加工和遗传学，以促进标准化实践和促进新的培训体验 学生、研究员和教职员工。Biomarker Core的独特定位是将蛋白质组学、神经成像、 将VADRC的基因组数据管道转化为来自国家联合体的既定工作流程，并确保 VADRC仍然处于预防、大规模发现和治疗干预的前沿 阿尔茨海默病和相关痴呆症。

PROJECT SUMMARY – BIOMARKER CORE The Exploratory Vanderbilt Alzheimer’s Disease Research Center (VADRC) Biomarker Core will leverage Vanderbilt’s institutional strengths in proteomics, neuroimaging, and genetics to provide a scalable infrastructure that can support biomarker collection, storage, analysis, integration, and distribution. Under the leadership of Dr. Timothy Hohman, we have established Vanderbilt as the Genomics Core for the Preclinical Alzheimer’s Disease Consortium, established the Biomarker Core for a multi-site cohort and autopsy study of Alzheimer’s disease and dementia correlates of delirium, led multiple large-scale discovery and candidate proteomic analyses emphasizing novel markers of risk and resilience to Alzheimer’s disease, and established the Resilience from Alzheimer’s Disease database, a local biomarker data repository that harmonizes fluid, neuroimaging, and genomic data across 10+ independent cohort studies. For the P20, we will leverage our local rich infrastructure and resources to acquire robust fluid, neuroimaging, and genetic biomarkers for the Clinical Core and affiliated cohort studies within the VADRC. The Biomarker Core and Clinical Core will work closely to ensure proper collection of relevant biomarkers using established, standardized protocols reflecting current best practices. Fluid, neuroimaging, and genetic data will be processed and stored within an established relational database, and the Biomarker Core will work to ensure proper storage and processing of all samples and data, with multiple quality control measures in place. Samples collected by the Clinical Core will be integrated by the Biomarker Core into funded, ongoing projects that support the VADRC’s thematic focus on establishing effective prevention and treatment strategies for non-amyloid pathways of injury that commonly co-occur with core Alzheimer’s disease pathology. Examples include discovery proteomic projects using mass-spectrometry, neuroimaging projects through the Preclinical Alzheimer’s Disease Consortium, and genomics projects as part of the Alzheimer’s Disease Genetics Consortium and Alzheimer’s Disease Sequencing Project. All data will be harmonized with large-scale cohort studies, and the Biomarker Core will coordinate with the Administrative Core to distribute all biomarker data to support local and national research activities. The Biomarker Core will also promote educational activities in biospecimen collection, neuroimage processing, and genetics to promote standardized practices and facilitate novel training experiences for students, fellows, and faculty. The Biomarker Core is uniquely positioned to integrate proteomic, neuroimaging, and genomic data pipelines for the VADRC into well-established workflows from national consortia and ensure that the VADRC remains at the forefront of prevention, large-scale discovery, and therapeutic intervention of Alzheimer’s disease and related dementias.